Incyte Corp (INCY)
$85.79
1.64 (1.88%)
INCY Stock Quote Delayed 15 Minutes
Previous Close
$85.79
Market Cap
18.18B
PE Ratio
-112.88
EPS
-0.76
Volume (Avg. Vol.)
1.13M
Day's Range
85.74 - 87.77
52-Week Range
57.00 - 89.30
Dividend & Yield
N/A (N/A)
INCY Stock Predictions, Articles, and Incyte Corp News
Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
Nasdaq Today: Maintaining Altitude Amid Uncertainty
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
3 Big Stock Charts for Wednesday: Incyte, FMC and LyondellBasell
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
3 Big Stock Charts for Wednesday: Cabot Oil & Gas, Incyte and Sempra Energy
The stock charts of COG, INCY and SRE are worth a closer technical look at the midpoint of the trading week.
3 Big Stock Charts for Monday: Pfizer, MGM Resorts and Incyte
The stock charts of PFE, INCY and MGM are finally making good on previously-suggested promise.
3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.
3 Big Stock Charts for Monday: Entergy, Incyte and SL Green Realty
The stock charts of SLG, INCY and ETR are shaping up as the best trading bets as the new week kicks off.
Incyte Corporation Stock Plunges on Melanoma Drug Trial Failure
Incyte (INCY) was falling hard on Friday following news of a failed Phase 3 drug trial for its melanoma drug epacadostat.
10 Deceptively Bad Stocks to Sell Before You’re Pranked
If you’re itching to buy, avoid these stocks at all costs. Here's what makes them stocks to sell for all wise investors.
Vapid Earnings Visibility Restrict Incyte (INCY) Rating
Incyte Corp (NASDAQ:INCY) is a $22.2 billion in market value member of the Biotechnology GICS industry group where Portfolio Grader's current ranking for INCY puts it 171 among the 349 companies in this industry group, placing it in the top half. INCY is ranked in the third quartile of the sector with a ranking of 402 among the 785 companies in the sector and number 2,601 in the 5000 company Portfolio Grader company universe.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
